Intravenous immune globulin reduces the need for exchange transfusions in Rhesus and AB0 incompatibility

Acta Paediatrica, International Journal of Paediatrics

Volumn 97, Issue 10, 2008, Pages 1362-1365

  Huizing, K M N ^a,b,c   Roislien J ^d   Hansen, T W R ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

ABO incompatibility; Exchange transfusion; Intravenous immune globulin; Neonate; Rh incompatibility

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; COHORT ANALYSIS; CONTROLLED STUDY; EXCHANGE BLOOD TRANSFUSION; FEMALE; HUMAN; INFANT; INSTITUTIONAL ETHICS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTOTHERAPY; PRIORITY JOURNAL; RHESUS INCOMPATIBILITY; STATISTICAL SIGNIFICANCE;

ABO BLOOD-GROUP SYSTEM; BILIRUBIN; BLOOD GROUP INCOMPATIBILITY; CONFIDENCE INTERVALS; EXCHANGE TRANSFUSION, WHOLE BLOOD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; MEDICAL RECORDS; NORWAY; ODDS RATIO; PHOTOTHERAPY; QUALITY CONTROL; RETROSPECTIVE STUDIES; RH ISOIMMUNIZATION; TIME FACTORS;

EID: 51349110913     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2008.00915.x     Document Type: Article

References (21)

1. Wallerstein H. Treatment of severe erythroblastosis by simultaneous removal and replacement of blood of the newborn. Science 1946 103 : 583 4.
2. Diamond LK, Allen FH Jr., Thomas WO Jr. Erythroblastosis fetalis: VII. Treatment with exchange transfusion. N Engl J Med 1951 244 : 39 49.
3. Cremer RJ. Influence of light on the hyperbilirubinaemia of infants. Lancet 1958 : 1 : 1094 7.
4. Obes-Polleri J, Hill WS. La fototerapia en las icterícias del recien nacido. Rev Chil Ped 1964 25 : 638.
5. Lucey JF, Ferreiro M, Hewitt J. Prevention of hyperbilirubinemia of prematurity by phototherapy. Pediatrics 1968 40 : 1047 54.
6. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002 3 : CD003313.
7. Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K. High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood type incompatibility. Acta Paediatr Scand 1991 80 : 163 6.
8. Rubo J, Albrecht K, Lasch P, Laufkotter E, Leititis J, Marsan D, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh haemolytic disease. J Pediatr 1992 121 : 93 9.
9. Daolu T, Ovali F, Samanci N, Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995 23 : 264 71.
10. Alpay F, Sarici SU, Okutan V, Erdem G, Ozcan O, Gokcay E. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999 88 : 216 9.
11. Miqdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinaemia in AB0 hemolytic disease of the newborn. J Matern Fetal Neonatal Med 2004 16 : 163 6.
12. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Fetal Neonatal Ed 2003 88 : F6 10.
13. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004 114 : 297 316.
14. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 1 : 1228 31.
15. Berlin G, Selbing A, Ryden G. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1988 325 : 1153.
16. De la Camara C, Arrieta R, Gonzalez A, Iglesias E, Omenaca F. Intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med 1988 318 : 519.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Aut Ctr 1974 19 : 716 23.
18. McCulloch CE, Searle RS. Generalized, linear and mixed models. New York : John Wiley & Sons, 2001.
19. Laster LL, Johnson MF. Non-inferiority trials: the 'at least as good as' criterion. Statistics Med 2003 22 : 187 200.
20. Snappin SM. Commentary: noninferiority trials. Curr Control Trials Cardiovasc Med 2000 1 : 19 21.
21. Zipursky A, Bowman JM. Isoimmune hemolytic diseases. In : Nathan DG, Oski FA, editors. Hematology of infancy and childhood. 4th ed. Philadelphia : W.B. Saunders Company, 1993 : 44 73.